Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 14/20 | 0.40 |
| ▸ | DRD3 | P35462 | 14/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13664449 | 0.93 | USP30 (0.40) | MAPTPOLBGAATDP1L3MBTL1 | |
| SCHEMBL13664330 | 0.86 | KMT2A (0.52) | MAPTSMN1; SMN2POLBGAATDP1 | |
| SCHEMBL13664329 | 0.86 | CNR1 (0.46) | DRD2MAPTDRD4SMN1; SMN2POLB | |
| SCHEMBL13664143 | 0.85 | POLB (0.46) | MAPTPOLBGAATDP1L3MBTL1 | |
| SCHEMBL13664373 | 0.85 | POLB (0.46) | MAPTPOLBGAATDP1L3MBTL1 | |
| SCHEMBL13664378 | 0.85 | KDM4E (0.48) | DRD2DRD3MAPTDRD4RAB9A | |
| SCHEMBL13664411 | 0.85 | SLC6A4 (0.47) | DRD3MAPTRAB9ASMN1; SMN2POLB | |
| SCHEMBL13664349 | 0.84 | CNR1 (0.46) | DRD2MAPTDRD4SMN1; SMN2POLB | |
| SCHEMBL13664403 | 0.84 | L3MBTL1 (0.46) | MAPTPOLBGAATDP1L3MBTL1 | |
| SCHEMBL13664409 | 0.84 | SLC6A4 (0.46) | DRD2DRD3MAPTDRD4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | GIPR, GPR119, GLP1R | DRD2 985/4885DRD3 900/4885MAPT 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.